Literature DB >> 8981175

Value of nocturnal penile tumescence and rigidity (NPTR) recording in impotent patients with multiple sclerosis.

F Staerman1, P Guiraud, P Coeurdacier, D Menard, G Edan, B Lobel.   

Abstract

The etiology of impotence in patients with multiple sclerosis (MS) is difficult to assess due to the possibility of normal nocturnal penile tumescence and rigidity (NPTR) recording despite neurologic involvement. Sixteen patients with MS and impotence were studied with Rigiscan, cavernous artery doppler, neurophysiological tests and intracavernous injection of PGE1. When more restrictive criteria of normality than usual are used for Rigiscan (rigidity > or = 80% and/or duration > 30 minutes), an inverse relationship between NPTR recording and sexuality score or PGE1 dose is reported. No significant difference is noted for neurophysiological tests. With such criteria, Rigiscan alone or combined with intracavernous PGE1 is a valuable means to differentiate neurogenic from psychogenic impotence in MS patients. Neurophysiological tests are of limited clinical value.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8981175

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  3 in total

Review 1.  [Influence of neurological diseases on partnership and sexuality. Particularly in view of multiple sclerosis and Parkinson's disease].

Authors:  D Goecker; D Rösing; K M Beier
Journal:  Urologe A       Date:  2006-08       Impact factor: 0.639

Review 2.  Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management.

Authors:  Sophie G Fletcher; Wanda Castro-Borrero; Gina Remington; Katherine Treadaway; Gary E Lemack; Elliot M Frohman
Journal:  Nat Clin Pract Urol       Date:  2009-02

Review 3.  Autonomic Dysregulation in Multiple Sclerosis.

Authors:  Alexandra Pintér; Domonkos Cseh; Adrienn Sárközi; Ben M Illigens; Timo Siepmann
Journal:  Int J Mol Sci       Date:  2015-07-24       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.